Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-03-08
2005-03-08
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S135100, C424S136100, C424S139100, C424S144100, C424S155100, C424S174100, C424S178100, C424S181100, C424S183100, C424S001490
Reexamination Certificate
active
06863887
ABSTRACT:
The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.
REFERENCES:
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 5543503 (1996-08-01), Chuntharapai et al.
patent: 5776457 (1998-07-01), Lee et al.
patent: 5798229 (1998-08-01), Strittmatter et al.
patent: 5840856 (1998-11-01), Chuntharapai et al.
patent: 1 072 273 (2001-01-01), None
patent: 9217497 (1992-10-01), None
patent: 9947158 (1999-09-01), None
patent: 9950461 (1999-10-01), None
patent: 0009152 (2000-02-01), None
Oka et al, Cancer Research, 1993, vol. 53, pp. 1696-1701.*
Weeraratna et al, Clinical Cancer Research, 1997, vol. 3, pp. 2295-2300.*
Pilkington et al (Molecular Immunology, vol. 33, pp. 439-450, 1996).*
The abstract of Sehgal et al (Proceedings of the American Association for Cancer research, 1998, vol. 39, pp. 228.*
Wick et al (Cancer Letters, 1997, vol. 118, pp. 161-172).*
Accession No. P30991, Jul. 1, 1993.*
Dorland's Medical Dictionary, 28th edition, 1994.*
Stedman's Medical Dictionary, 27th Edition, 2000.*
Sehgal et al., “CXCR-4, a Chemokine Receptor, is Overexpressed in and Required for Proliferation of Glioblastoma Tumor Cells,”J. Surg. Oncol. 69:99-104 (1998).
Sehgal et al., “Molecular Characterization of CXCR-4: A Potential Brain Tumor-Associated Gene,”J. Surg. Oncol. 69:239-248 (1998).
Bleul et al., “The Lymphocyte Chemoattractant SDF-1 is a Ligand For LESTR/fusin and Blocks HIV-1 Entry,”Nature382:829-832 (1996).
Bogler et al., “Thep53Gene and Its Role in Human Brain Tumors,”GLIA15: 308-327 (1995).
Broaddus et al., “Antiproliferation Effect of c-mycAntisense Phosphorothioate Oligodeoxynucleotides in Malignant Glioma Cells,”Neurosurgery41:908-915 (1997).
De Risi et al., “Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer,”Nature, Genetics14:457 (1996).
Doranz et al., “Chemokine Receptors as Fusion Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1),”Immunol. Res. 16:15 (1997).
Eibl et al., “Expression of Variant CD44 Epitopes in Human Astrocytic Brain Tumors,”J. of Neurooncol., U26:165-170 (1995).
Endres et al., “CD4-Independent Infection to HIV-2 Is Mediated by Fusion/CDCR4,”Cell87:745-756 (1996).
Engelhard et al., “Molecular Characterization of Glioblastoma Cell Differentiation,”Neurosurgery41:886-897 (1997).
Faillot et al., “A Phase I Study of an Anti-epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas,”Neurosurgery, 39:478-483 (1996).
Federsppiel et al., “Molecular Cloning of the cDNA and Chromosomal Localization of the Gene for a Putative Seven-Transmembrane Segment (7-TMS) Receptor Isolated from Human Spleen,”Genomics16:707-712 (1993).
Feng et al., “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor,”Science272:872-877 (1996).
Furnari et al., “Genetics and Malignant Progression of Human Brain Tumours,”Cancer Surv. 25:233-275 (1995).
Haribabu et al., “Regulation of Human Chemokine Receptors CDCR4,”J. Biol. Chem. 272-28726 (1997).
Huang et al., “Egr-1 Negatively Regulates Human Tumor Cell Growth via the DNA-binding Domain,”Cancer Research55:5054-5062 (1995).
Jung et al., “Increased Levels ofp21WAF1/Cip1in Human Brain Tumors,”Oncogene11:2021-2028 (1995).
Laws et al., “Brain Tumors,”CA Cancer J. Clin. 43:263-271 (1993).
Loetscher et al., “Cloning of a Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed in Leukocytes,”J. Biol. Chem. 269:232-237 (1994).
Nagasawa et al., “Defects of B-Cell Lymphopoiesis and Bone-Marrow Mylelopoesis in Mice Lacking the CDC Chemokine PBSF/SDF-1,”Nature382:635638 (1996).
Nomura et al., “Molecular Cloning of cDNAs Encoding a LD78 Receptor and Putative Leukocyte Chemotactic Peptide Receptors,”Int. Immunol. 5:1239-1249 (1993).
Oberlin et al., “The CXC Chemokine SDF-1 is the Ligand for LESTR/fusin and Prevents Infection by T-Cell-Line-Adapted HIV-1,”Nature382:833-835 (1996).
Parker et al., “Cancer Statistics, 1996,”CA Cancer J. Clin. 46:5-28 (1996).
Previtali et al., “α6β4 and α6β1 Integrins in Astrocytomas and Other CNS Tumors,”J. Neuropathol. Exp. Neurol. 55:456-465 (1996).
Sehgal et al., “Characterization of C4-2 as a Tumor-Suppressor Gene in Human Brain Tumors,”J. Surg. Oncol. 64:102-108 (1997).
Sehgal et al., “Cloning, Sequence, and Developmental Expression Analysis of C4-2, a Potential Brain Tumor-Suppressor Gene,”J. Surg. Oncol. 65:249-257 (1997).
Sehgal, “Application of the Differential Hybridization of Atlas ™ Human Expression Arrays Technique in the Identification of Differentially Expressed Genes in Human Glioblastoma Multiforme Tumor Tissue,”J. Surg. Oncol. 67:234-241 (1998).
Takano et al., “Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients,”Cancer Res. 56:2185-2190 (1996).
Tsuzuki et al., “Alterations of Retinoblastoma, p53, p16(CDKN2), and p15 Genes in Human Astrocytomas,”Cancer78:287-293 (1996).
vonDiemling et al., “Molecular Pathways in the Formation of Gliomas,”GLIA15:328-338 (1995).
Yamamoto et al., “Differential Expression of Membrane-Type Matrix Metalloproteinase and Its Correlation with Gelatinase A Activation in Human Malignant Brain Tumors in Vivo and in Vitro,”Cancer Res. 56: 384-392 (1996).
Boynton Alton L.
Murphy Bridgette
Sehgal Anil
Canella Karen A.
Northwest Biotherapeutics, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Therapeutic and diagnostic applications based on the role of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic applications based on the role of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic applications based on the role of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3398620